Figure 1
miR-301a deletion reduces lung tumor development and increases survival in KrasLA2 mice. (a) Expression of miR-301a in lung tumors and spleens from KrasLA2 mice. Total RNA of lung and spleen was extracted from WT and KrasLA2 mutant littermates (n=5 per group) at 9, 13, and 18 weeks of age. (b–d) Representative gross (b) and hematoxylin and eosin (H&E) histological sections (c, d) of lungs isolated from KrasLA2 (n=5) and miR-301a−/−;KrasLA2 (n=6) mice at 18 weeks of age. Images in d show the enlargement of boxed areas from c. Scale bars, 5 mm (b, c) or 500 μm (d). (e) Total number of tumor nodules on the lung surface of KrasLA2 (n=5) and miR-301a−/−;KrasLA2 (n=6) littermates at 18 weeks of age. (f) Distribution of various-sized lung tumors from KrasLA2 (n=5) and miR-301a−/−;KrasLA2 (n=6) mice at 18 weeks of age. (g) Tumor spectrum in KrasLA2 (n=34) and miR-301a−/−;KrasLA2 (n=28) mice. (h) Survival curves of KrasLA2 (n=34) and miR-301a−/−;KrasLA2 (n=28) mice (P<0.0001). Values are means±s.d. **P⩽0.01 indicates the significance of the differences between experimental groups.
